Category: Corporate Venture Capital
MS Ventures is the strategic, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. We invest globally in emerging biotechnology companies that develop products and or technologies that have the potential to significantly improve patient outcomes.
Along with the €100 million MS Ventures fund, our team also manages the €30 million Entrepreneur Partnership Program fund established to support the creation of spin-offs and the € 10 million Israel Bioincubator Fund, focused on pre-seed and seed opportunities coming out of Israel.
Israel Bioincubator: MS Ventures Israel Bioincubator Fund is a strategic initiative designed to stimulate innovation by bridging the gap between academic research and the biotechnology industry in Israel. Launched in 2011 to invest in biomedical innovation in Israel, the Bioincubator offers both seed financing and access to dedicated laboratory facilities within our Israel based R&D center. Through the incubator initiative, we have committed to invest up to EUR 10 million in early stage opportunities.
|South Industrial Area 18 HaKishon St. Yavne 81220 Israel|
To update your company data, click here.